摘要
目的探讨大肠癌和胃癌患者血清β2-微球蛋白(β2-microglobulin,β2-MG)含量变化及其临床意义。方法用免疫比浊法检测30例大肠癌和30例胃癌以及30例正常健康人血清β2-MG含量;动态检测大肠癌和胃癌手术前后β2-MG含量变化。结果大肠癌组和胃癌组血清中β2-MG含量均明显高于健康对照组(P<0.01);大肠癌和胃癌术前血清β2-MG含量增高者,术后含量均明显降低(P<0.01)。结论检测血清β2-MG含量变化在大肠癌和胃癌辅助诊断以及疗效判断方面具有重要临床意义。
Objective To observe level change of serum β2-microglobulin （β2-MG） in patients with colon cancer and gastric cancer and discuss clinical significance of immunoturbidimetric assay. Methods The content of serum β2-MG was detected in 30 patients with colon cancer, 30 with gastric cancer and 30 normal persons by means of immunoturbidimetric assay. Dynamic detection of content of β2-MG was done via automated chemistry analyser before and after operation for colon cancer and gastric cancer. Results The level of serum β2-MG in patients with colon cancer and gastric cancer was much higher than that in normal persons （P〈0.05）. Preoperative high level of serum β2-MG in patients with colon cancer and gastric cancer were reduced dramatically after operation （ P〈0.01）. Conclusion Immunoturbidimetric assay de- tecting level changes of serum β2-MG plays an important role in assisting diagnosis and judgment of therapeutic effects for colon cancer and gastric cancer.
出处
《消化外科》
CSCD
2006年第5期318-320,共3页
Journal of Digestive Surgery
关键词
Β2-微球蛋白
大肠肿瘤
胃肿瘤
免疫比浊法
β2-microglobulin
Colon cancer
Gastric cancer
Immunoturbidimetric assay
